January 29, 2021
Member/Center Highlights
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
Northeast Ohio leaders in healthcare and higher education partner with State, announce historic investment in Cleveland Innovation District
Ohio Governor Mike DeWine and Lt. Governor Jon Husted on Monday announced the Cleveland Innovation District, a transformational collaboration of Northeast Ohio's leading healthcare and higher education institutions.

The Cleveland Innovation District brings together Case Western Reserve University, Cleveland Clinic, University Hospitals, The MetroHealth System and Cleveland State University in partnership with the Ohio Development Services Agency and JobsOhio to drive advancements in healthcare education, research and development. The initiative's goal is to bring 20,000 new jobs to the area over 10 years, an expected economic impact of $3 billion for Cleveland and Ohio that also generates $3 billion in research activity.

In a message to the Case Western Reserve University Community this week, Interim President Scott Cowen noted, "If we succeed, Northeast Ohio will take its place among the nation’s preeminent hubs for health care and biomedical research." Additional details about the agreement will be shared with the university community as they become available. "We will concentrate on advancing our expertise in areas that include but are not limited to artificial intelligence, big data, and drug development, with a particular emphasis on their implications for cancer, infectious diseases, neurological disorders and cardiac issues," said Cowen.
Concurrent chemotherapy and antibiotic use associated with epithelial ovarian cancer outcomes
Researchers at Cleveland Clinic's Ob/Gyn & Women's Health Institute and Lerner Research Institute recently published a retrospective study in Gynecologic Oncology which found that women with newly diagnosed stage III or IV epithelial ovarian cancer and received antibiotics following cytoreductive surgery and platinum chemotherapy had worse outcomes in comparison to those who did not receive antibiotics.

Cleveland Clinic's Peter G. Rose, MD, Ofer Reizes, PhD and Roberto Vargas, MD are co-authors on the. study and members of the Case Comprehensive Cancer Center.
5th Annual Cancer Disparities Symposium (Virtual)
March 4-5, 2021

Today is the last day to submit abstracts for presentation at the 5th Annual Cancer Disparities Symposium, Navigating Cancer Disparities: Lessons Learned and How to Move Forward.

Abstracts will be divided into two tracks: Scientific Research and Community Programs.
  • Students who submit an abstract are able to register for FREE.
  • Meritorious abstracts will be selected for pre-recorded presentations.
  • Abstracts must be submitted electronically by 5 pm ET on Friday, January 29, 2021.

About the Symposium
This multi-disciplinary event will appeal to researchers, clinicians, health professionals, community outreach groups, community-based organizations, patient advocates and trainees. Keynote presentations will be delivered by renowned disparities researchers and community leaders, and a poster session highlighting academic research and community programs will provide a showcase of the depth and breadth of work happening in this field. 

Though the symposium is happening virtually, attendees will experience the conference using Whova, our official web-based conference app, to view presentations and ask questions in real-time, as well as network with others behind the scenes.
Session topics include: 

  • COVID19 and cancer disparities
  • Improving the participation of minority and underserved populations in cancer clinical trials
  • Interplay of biology and social determinants of cancer disparities
  • The many pains of cancer: physical, emotional and financial

Plus, attendees will have the opportunity to participate in an in-depth discussion of the book Just Medicine: A Cure for Racial Inequality in American Health Care by Dayna Bowen Matthew. 
Keynote Speakers
Otis W. Brawley, MD, an internationally-recognized expert in cancer prevention and control, will present the symposium's Scientific Keynote His work is focused on closing racial, economic and social disparities in prevention, detection and treatment of cancer in the United States and worldwide.

Worta McCaskill-Stevens, MD, a medical oncologist nationally known for her expertise in bringing clinical trials to the community will present the Community Keynote. Dr. McCaskill-Stevens is Chief of the Community Oncology and Prevention Trials Research Group, which houses the National Cancer Institute (NCI) Community Oncology Research Program (NCORP), a community-based clinical trials network launched in 2014.
Update: Submissions to the Case Comprehensive Cancer Center
Recent security measures across the Cleveland Clinic network made the Case CCC Marketing and Communications Request Form inaccessible to members of our community.

A new submission form is now available for use. There is a lot of important work and exciting accomplishments occurring throughout and related to the Case Comprehensive Cancer Center - and we want to know all about it! As a large center that spans three institutions, our team is making an effort to streamline distribution and project requests in order to best serve our membership and community.

As a reminder, this form may be used to submit any of the following requests:
  • Assistance creating marketing materials
  • Newsletter and/or digital communications submissions (screens in the WRB, email blasts)
  • Updates to existing web pages under the Case CCC
  • New web pages and biographies under the Case CCC

Let our team know what you think about the form - we're happy to help out and hear your suggestions! Reach out to Case CCC marketing and communications anytime at cancer@case.edu.
Department of Nutrition seeking postdoc to study cancer cell biology
A postdoctoral position is available at the School of Medicine of Case Western Reserve University and the Case Comprehensive Cancer Center to study the molecular mechanisms by which specific oncogene products drive tumorigenesis and invasiveness in colorectal cancer. The primary goal of the project is to develop novel, target-specific inhibitors for studies in cell and animal models of the disease.

The postdoc will work independently on research projects under the supervision of the principal investigator. The candidate must have a strong foundation and experience in all aspects of cell signaling and cancer cell biology. The candidate will be expected to contribute to the preparation of manuscripts and reports, and to regularly present their findings at various internal and external meetings. Candidates must have an MD and/or PhD with relevant experience, a strong record of productivity with evidence of first-author publications, and excellent communication skills. This is an outstanding opportunity for highly motivated individuals with strong bench and organizational skills. Competitive salary commensurate with experience, and benefits; NIH funded.

Interested applicants should submit a CV, a letter of interest and contact information of three individuals that can provide academic references upon request to:

Dr. D. Manor
School of Medicine, WG-48
Case Western Reserve University
Cleveland, OH 44106

Diversity Statement: In employment, as in education, Case Western Reserve University is committed to Equal Opportunity and Diversity. Women, veterans, members of underrepresented minority groups, and individuals with disabilities are encouraged to apply.
What's Coming Up
Mark Your Calendar
Cancer Center Seminar Series
TODAY, January 22, 2021, 12p via Zoom
Today's Cancer Center Seminar features Dan Theodorescu, MD, PhD presenting, "Improving Immune Checkpoint Inhibitor in Cancer" on behalf of the GU Malignancies Program at noon via Zoom.

Dr. Theodorescu is the PHASE ONE Foundation Distinguished Chair, Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai and professor of surgery, pathology and laboratory medicine.

Dr. Theodorescu is internationally known for his work on the molecular mechanisms driving bladder cancer and tools that determine drug response as well as discovery of new drugs for bladder and other cancer types. Examples include discovery of genes that regulate tumor growth and metastasis and novel biomarkers and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG 1314) clinical trials. He also conceptualized the approach and then led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in cancer, now patented and in commercial development.

A program mini-retreat will follow Dr. Theodorescu's talk from 2-4 pm via Zoom.
Cancer Center Seminar Series
Friday, January 29, 2021, 12p via Zoom
Next week's Cancer Center Seminar features Mei Zhang, PhD presenting, "Improving Immune Checkpoint Inhibitor in Cancer" on behalf of the Developmental Therapeutics Program.

Dr. Zhang’s laboratory looks at understanding how biomaterials and cell-based therapeutics can be designed to correct suppressive immune responses in solid tumor cancers. Her aim is to develop immunoengineering technology (biomaterials, drug delivery system and nanotechnology) to shift the balance of the immune response between activation and suppression. Where possible, the hope is to exploit research discovery to improve patient outcomes by enhancing responses to conventional, targeted or immunotherapeutic. Currently, the laboratory focuses primarily on immunotherapy pancreas cancer, advanced melanoma and osteosarcoma.
Additional Upcoming Events
AACR Virtual Meeting: COVID-19 and Cancer
February 3-5, 2021
Join thought leaders from academia, government, and industry for AACR’s 2021 COVID-19 and Cancer virtual meeting. Emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer will be presented in a mix of keynote lectures, forums, and symposia.

Session topics include:
  • Biology of COVID-19 and Cancer
  • Cancer Prevention and Early Detection
  • Continuity of Cancer Care
  • Critical Care and Outpatient Management
  • Effects of Cancer Treatments on COVID-19
  • Health Inequities and Disparities
  • Immunology and Pathogenesis
  • Long-term Effects and Survivorship
  • Risk Factors and Comorbidities 
  • Trials in Progress
  • Vaccines
NCCN 2021 Virtual Congress™: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS)
February 12, 2021
Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies. Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

The NCCN 2021 Virtual Congress™: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS) will provide expert insights on the current standard of care for patients with breast cancer and include the latest clinical research updates from the 2020 SABCS to assist clinicians in formulating breast cancer management strategies.
Breast Cancer Update: Review of Breast Cancer Symposia
February 17, 2021
This review course will summarize highlights from the national meetings, with a focus on the clinical implications of the new information presented at these meetings.

Medical oncologists, breast surgeons, radiation oncologists, women's health, nurses, nurse practitioners, physician assistants, residents and fellows and other health care providers with an interest in the management of patients with breast cancer should attend this course.
Management of Checkpoint Inhibitor-Related Toxicity Virtual Updates
March 5, 2021
The goal of the program is to bring together a multidisciplinary group of clinicians to share expertise and improve the care of patients receiving immune checkpoint inhibitor therapies.

Specialists in dermatology, endocrinology, gastroenterology, oncology, internal medicine, rheumatology/ immunology, nurses, nurse practitioners, physician assistants and residents/ fellows are invited to attend.
4th Annual International PTEN Symposium
Monday, March 15, 2021
The Genomic Medicine Institute and Center for Personalized Genetic Healthcare at Cleveland Clinic invite you to join the virtual 4th Annual International PTEN Symposium: From Patient-Centered Research to Clinical Care. They are planning an engaging day with an emphasis on advances in the diagnosis, management and treatment of patients with PTEN Hamartoma Tumor Syndrome (PHTS).

Pier Paolo Pandolfi, MD, PhD, FRCP, senior scientist at the Renown Institute for Cancer and honorary professor of molecular biology at the University of Turin, will deliver the morning keynote address. Neil Friedman, MBChB, pediatric neurologist and director of quality, outcomes, and innovation at Barrow Neurological Institute at Phoenix Children’s Hospital, will deliver the afternoon keynote address on the neurological spectrum of PHTS. Other topics include hormone use and high-risk patients, gynecological cancer risks, updates on PTEN clinical trials, and autism. Please refer to the symposium agenda for more details about this year’s speakers and topics.
NCCN Virtual Annual Conference
March 18-20, 2021
In response to the ongoing COVID-19 pandemic, the National Comprehensive Cancer Network (NCCN) has transitioned the NCCN 2021 Annual Conference to a to a live virtual format.

Designed to meet the needs and improve the competence and performance of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals who manage the care of patients with cancer, this three-day virtual event will offer more than 35 educational sessions covering a range of topics such as:

  • Updates to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 
  • New and emerging therapies, controversies in treatment, and best practices in the delivery of oncology care  
  • Issues surrounding HPV vaccination  
  • Racial disparities in guideline-adherent cancer care  
  • Effects of the pandemic on cancer care  
  • Best practices for incorporating patient-reported outcomes into oncology care

Throughout this three-day virtual event, educational sessions will include a mix of challenging case reviews, interactive polling, and moderated Q&A providing participants the opportunity to reinforce knowledge and develop strategies for the management of a variety of cancers.
AACR Annual Meeting 2021
April 10-15 and May 17-21, 2021 | Virtual
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.
AACI Clinical Research Innovation 13th Annual Meeting
July 13-15, 2021
Save the date! The 13th Annual AACI Clinical Research Innovation (CRI) Meeting will be held July 13-15, 2021. Information about the meeting format, abstract submissions, and registration will be made available in early 2021.
Funding Opportunities
Deadline: March 12, 2021

The Center for Reducing Health Disparities, established jointly by the MetroHealth System and Case Western Reserve University, seeks innovative pilot projects that partner with community organizations to better understand and/or reduce health disparities. Investigators from underrepresented groups are highly encouraged to apply.
Stand up to Cancer
Deadline: March 22, 2021

Stand Up To Cancer (SU2C) invites applications for participation in an Ideas Lab to establish the SU2C Head and Neck Cancer Research Team. The Research Team will bring new approaches to treating head and neck squamous cell carcinoma (HNSCC) cancer into the clinical setting, with a focus on HPV-related and Fanconi anemia (FA)-related cancers. The funding available for the program is up to $3,250,000 over the 3-year grant program.
In The News
ideastream - December 28, 2020
“If people have had allergic reactions to vaccines in the past—other vaccines—they are still encouraged to take it with monitoring after receiving the vaccine," said Mark Cameron, PhD. Cameron is an immunologist at Case Western Reserve University and member of the Case CCC.
Crain's Cleveland Business - January 24, 2021
Tom Zenty will retire as president and CEO of University Hospitals (UH) at the end of this month, capping nearly two decades of leading the system. In that time, UH has built new hospitals and locations, added existing community hospitals into the system and renovated and expanded facilities.
From The NIH
Request for Information (RFI) regarding opportunities for new national programs at the National Cancer Institute’s (NCI) Frederick National Laboratory for Cancer Research
NCI has released a Request for Information (RFI) seeking input from the cancer research community on the most important needs and promising opportunities in cancer research that are difficult to address on an individual scale but could be tackled through the NCI Frederick National Laboratory for Cancer Research. This is part of a planning effort to identify unique, large-scale programs of national significance that the FNLCR could support in the interest of the entire cancer research community.

Email responses to RFI_NewNationalPrograms@nih.gov and place "RFI Response" in the subject line. Responses will be accepted through February 19, 2021.
Weekly NIH Funding Opportunities and Notices
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.